Evaluationof cyclosporineAeyeabsorption after administrationof liposomalor conventionalformsin animalmodel

Objective(s):Many researcheshave investigatedtheeffectsof topicalcyclosporineAontheeyesurfacelayers’diseases. Today themain limitation in cyclosporineapplication is the lowpermeationofthedrug intotheposteriorsegmentsoftheeye.Theaimofpresentstudywasto formulate highpermeabledosage form.MaterialsandMethods:Forhighercornealdrugabsorptionanddrugconcentrationin theposteriorsegmentsofthe eye,onenanoliposomalformulationcontaining 0.5mg/ml cyclosporine A wasprepared.Liposomal formulationandthecommercialproduct (Restasis®)wereinstilledintherightandleft eyesof the rabbits,respectively.Rabbitswerekilledinthe3,7,14and28daysofstudyandthensamples were extracted.Results:Meansizeofliposomalformulationwas 129.3±0.9 nmand its zetapotentialwas-5.5±2.3mV.Resultsofocular analysisshowedthatthe liposomalformulationcouldincreasetheconcentrationofthedrugintheaqueousandvitreouslikeRestasis®.But, itcouldnotmakeasignificantdifferenceinconcentrationofthedrug in aqueous and vitreous humorcompared toRestasis®.Conclusion:We canstatethatliposomeswiththesame compositionasour formulationarenotmoreefficientthanmicroemulsionsforcyclosporineasophthalmicdrug carrier.

کلیدواژه ها:

Cyclosporine A ، Nanoliposome ، Restasis® ، Posterior segment